SUBSCRIBE Blog with us: BLOGbiotech

Breaking News

• Email
• Print
• Share
• More News

Jul 19 2007, 3:00 AM EST

Arpida Adds a Late Stage Antifungal to its Pipeline Through Acqusition of TLT Medical Ltd.

PRNEWSWIRE

REINACH and BASEL, Switzerland, July 19 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the acquisition of TLT Medical Ltd., a Swiss privately-owned biopharmaceutical company with an innovative onychomycosis (OM) therapy. European regulatory authorities have granted authorisation to initiate a pivotal Phase III clinical trial that aims to demonstrate superiority of the TLT therapy compared to the standard of care topical treatment for mild to moderate OM. Enrolment is expected to start in the short term and filing for approval could be expected in late 2008 or early 2009.

Onychomycosis is a fungal infection that affects the toenails or fingernails of an estimated 30 million people in the USA alone. The global market for OM is currently estimated at USD 2 billion and is expected to grow at double-digit rates over the coming years. Novartis Lamisil (terbinafine) is the current market leader with sales of USD 978 million in 2006.

The TLT therapy is targeted to treat fungal infections of the nails of fingers and toes and combines a novel formulation of terbinafine (the active ingredient of Lamisil, which has already been used in over 20 million patients) with an innovative, proprietary, local treatment. This targeted approach could consequently offer significant advantages by providing effective therapy while at the same time avoiding systemic exposure and bypassing the potential side effects of oral treatments. The technology is licensed from Novartis, based on an unencumbered, exclusive worldwide agreement.

Dr Andr Lamotte, Chairman of the Board of Directors of Arpida Ltd., commented The acquisition once more reiterates Arpidas focus on the discovery and development of novel pharmaceutical products for the treatment of microbial infections. This innovative therapy provides an attractive point of entry into the growing antifungal market and creates synergy with Arpidas existing knowledge-base.

Dr Alfredo Bruno, the inventor of the therapy and founder of TLT Medical Ltd., added: We are excited about the opportunity offered by teaming up with Arpida. We get access to a large pool of expertise and experience in antimicrobial research and development. This should enable us to drive the development of our OM therapy with increased vigour.

Dr Khalid Islam, president and CEO of Arpida Ltd., added: The founders of TLT Medical Ltd. have done a splendid job in getting this therapy to an advanced stage of development. Considering the low risk associated with this late stage product and the high potential in the onychomycosis treatment we believe that it will significantly enhance the Arpida pipeline and provide additional near term market opportunities. We are looking forward to working with the TLT team in accelerating their progress.

The transaction regarding the onychomycosis treatment comprises an upfront payment as well as success-dependent future payments to the former shareholders of TLT Medical Ltd. which could total up to CHF 57 million. Up to CHF 5 million will be paid in Arpida shares to be issued out of authorised capital, with the remainder payable in cash. The closing of the agreement is expected to occur by mid-August. Arpida will finance the remainder of the TLT development expenses which are expected to total a single digit amount in CHF million.

Additional information on this topic can be found in the TLT factsheet which is added to this press release and is also available on www.arpida.com under Download centre.

Conference Call

Arpida will host a conference call to discuss this acquisition on 19 July 2007, at 2 pm CET.

    The dial-in numbers are:
    +41-(0)91-610-56-00 (Europe)
    +44-(0)207-107-0611 (UK)





	
Email
 
	
 Print
	

		
		
		  Share
		
	
	


		More News












 



				
				
				

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR